Evidence map›Paper›PMID 33044628›Full record

ArticleJournal of cancer research and clinical oncology2021

Prevalence and significance of M541L single nucleotide polymorphism in the central European cohort of gastrointestinal stromal tumor patients.

Karin Jasek, Marian Grendar, Andrea Stanclova, Bibiana Malicherova, Ivana Kasubova, Tatiana Burjanivova, Peter Szepe, Rachele Ciccocioppo, Luis Rodrigo, Robert Prosecky and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Trial
  2. Contribution of genetic polymorphism inJournal of gastrointestinal oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Karin JasekBiomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Marian GrendarBiomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Andrea StanclovaDepartment of Pathological Anatomy, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Bibiana MalicherovaBiomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Ivana KasubovaBiomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Tatiana BurjanivovaDepartment of Molecular Biology and Genomics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Peter SzepeDepartment of Pathological Anatomy, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Rachele CiccocioppoDepartment of Medicine, A.O.U.I. Policlinico G.B. Rossi and University of Verona, Verona, Italy.
Luis RodrigoFaculty of Medicine, University of Oviedo, Central University Hospital of Asturias (HUCA), Oviedo, Spain.
Robert Prosecky2nd Department of Internal Medicine, Faculty of Medicine, Masaryk University and St. Anne'S University Hospital, Brno, Czech Republic.
Peter KruzliakResearch and Development Services, Brno, Czech Republic. peter.kruzliak@savba.sk.ORCID http://orcid.org/0000-0002-7069-3784
Lukas PlankBiomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Zora LasabovaBiomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia. zora.lasabova@uniba.sk.
Comenius University Bratislava · SKElectronic Product Services (Czechia) · CZMasaryk University · CZUniversidad de Oviedo · ESUniversity of Verona · IT

Funding

Agentúra Ministerstva Školstva, Vedy, Výskumu a Športu SR VEGA-1/0380/18
6 · The paper itself

Abstract

backgroundSingle nucleotide polymorphisms can create a genetic microenvironment in some tumors that affects the course of treatment, resistance, etc. Whether single nucleotide polymorphisms have an impact on gastrointestinal stromal tumor (GIST) development and disease progression is not yet accurately verified. KIT SNP

aimThe aim of the study was the analysis of the biological and clinical significance of the KIT SNP MATERIALS AND

methodsParaffin sample tissues were obtained from the National GIST Register in Martin. Retrospective samples from 177 GIST patients were divided into several groups. Detection of SNP

resultsOverall, 29 samples out of 177 showed KIT SNP

conclusionOur results do not support the association between KIT SNP

Indexed as

Polymorphism, Single NucleotideAdolescentAdultAgedAged, 80 and overBiomarkers, TumorEuropeFemaleFollow-Up StudiesGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHumansMaleMiddle AgedPrognosisProto-Oncogene Proteins c-kitBiomarkers, TumorKIT protein, humanProto-Oncogene Proteins c-kitc.1621 A > Cc-KITGastrointestinal stromal tumorsM541LSingle nucleotide polymorphism

Identifiers

PMID33044628
PMCPMC11802002
OpenAlexW3092131223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.